CCIA
TAK icon

Campbell & Co Investment Adviser’s Takeda Pharmaceutical TAK Stock Holding History

Campbell & Co Investment Adviser’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45,981
Closed -$673K – 1393
2025
Q3 		$673K Buy
+45,981
New +$683K 0.05% 588
2023
Q4 		– Sell
-13,674
Closed -$212K – 1334
2023
Q3 		$212K Buy
+13,674
New +$212K 0.03% 829

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Campbell & Co Investment Adviser's TAK Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of Takeda Pharmaceutical (TAK) in Q4 2025, closing a stake of 45,981 shares — an estimated $673K sold.

Campbell & Co Investment Adviser first reported a position in TAK in Q3 2023 and held it in 2 quarters. The position peaked at $673K in Q3 2025. 349 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

  • Campbell & Co Investment Adviser reported no remaining Takeda Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 45,981 Takeda Pharmaceutical shares in Q4 2025, an estimated $673K.
  • Campbell & Co Investment Adviser first reported a position in Takeda Pharmaceutical in Q3 2023 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Takeda Pharmaceutical position peaked at $673K in Q3 2025.
  • 349 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.